|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
Our results indicate a role of DLC-1 in BC carcinogenesis.
|
12759748 |
2003 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells.
|
16024604 |
2005 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
These findings are consistent with a possible tumour suppressor function of DLEC1 in breast cancer.
|
20530412 |
2010 |
|
Malignant neoplasm of breast
|
0.360 |
PosttranslationalModification
|
disease |
BEFREE |
These data suggest that hypermethylation is responsible for silencing of DLC-1 gene in a limited portion of breast cancers.
|
15201975 |
2004 |
|
Malignant neoplasm of breast
|
0.360 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant neoplasm of breast
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The correlation between DLC-1 expression level and tumor progression and metastasis of breast cancer was negative.
|
22799310 |
2012 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
Furthermore, introduction of the DLC-1 cDNA abolished the in vivo tumorigenicity in nude mice, suggesting that the DLC-1 gene plays a role in breast cancer by acting as a bona fide tumor suppressor gene.
|
12545165 |
2003 |
|
Squamous cell carcinoma of esophagus
|
0.300 |
GeneticVariation
|
disease |
ORPHANET |
Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3.
|
10213508 |
1999 |
|
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
While the pathogenic relevance of the intronic polymorphism is not known, the low rate of mutation of the DLC-1 gene in HCC implies that genomic deletion and promoter methylation primarily account for the altered expression and tumor suppressive inactivation of the DLC-1 gene.
|
12792785 |
2003 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transfection of DLC-1 into 5 HCC cell lines (two with DLC-1 deletion and three with intact DLC-1) showed significant growth inhibition in these two HCC cell lines with deleted DLC-1 with both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and colony formation assays but not in three other HCC cell lines with intact DLC-1.
|
11118037 |
2000 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These observations thus support the notion that Dlc-1 protein is involved in hepatocarcinogenesis and has oncosuppressive activity in HCC.
|
14647417 |
2004 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DLC-1 (deleted in liver cancer) gene is frequently deleted in hepatocellular carcinoma.
|
12813468 |
2003 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DLC-1 was found to be deleted or downregulated in a significant number of HCCs.
|
12545165 |
2003 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Various important genes encoding tumor suppressors including P16, RASSF1A, DLC-1, RUNX3 and SOCS-1 are targets of epigenetic dysregulation during the development of HCC.
|
27271356 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DLC-1 (deleted in liver cancer 1) is a candidate tumor suppressor gene for hepatocellular carcinoma and other cancers.
|
12034501 |
2002 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DLEC1 was selected for further characterization in primary hepatocellular carcinomas and cell lines.
|
18191269 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, with real-time quantitative PCR, we found that DLC-1 mRNA was significantly underexpressed in HCCs when compared with the corresponding nontumorous livers (P < 0.0001).
|
14633684 |
2003 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To characterize its functions, we constructed recombinant adenovirus encoding the wild-type DLC-1 and examined its effects on behaviors of a hepatocellular carcinoma cell line (SNU-368), which does not express DLC-1.
|
17292327 |
2007 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
DLEC1 was selected for further characterization in primary hepatocellular carcinomas and cell lines.
|
18191269 |
2008 |
|
Abnormality of the voice
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Clinodactyly of the 5th toe
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Adult Liver Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
The deleted in liver cancer (DLC-1) gene at chromosome 8p21-22 is altered mainly by genomic deletion or aberrant promoter methylation in a large number of human cancers such as breast, liver, colon and prostate and is known to have an inhibitory effect on breast and liver tumor cell growth.
|
14661059 |
2004 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
DLC-1 may be a tumor suppressor gene in liver cancer as well as in other cancers.
|
9605766 |
1998 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
DLC-1 (deleted in liver cancer) gene is frequently deleted in hepatocellular carcinoma.
|
12813468 |
2003 |